Cambridge Life Sciences Ltd – Products – Clinical Chemistry

Cambridge Life Sciences - Products - Clinical Chemistry - Tumour Markers

Markers for Brain Injury - S100

Seralogical determination of increased S100 level is a sensitive serological indicator of brain damage after acute brain trauma. It is also clinically proven to be useful for determination and follow-up of malignant melanoma.

A number of studies have suggested the usefulness of serological S100 determination in the following conditions:

Neurological complications after ECC; correlation between S100 release in serum and neurological complications.
Major and minor head injury; S100 gives additional clinical information in brain injury owing to trauma and hypoxia compared to CT and MRI.
Stroke; diagnostic aid and early indicator of functional deficit.

S100 has been shown to be an independent indicator of poor prognosis in all-clinical stages of malignant melanoma and is useful for follow-up and monitoring of therapy of malignant melanoma.

S100 is a solid-phase non-competitive assay based on the direct sandwich technique for optimal clinical sensitivity, specificity and non-specific interference for determination of S100, ie S100A1B and S100BB. The assay is based on an antibody for S100B as catcher and HRP labelled MAb specific for S100B for detection.

Please select another Clinical Chemistry option:

Immunology Clinical Chemistry Urease Hp Tests Instrumentation